tastatic breast cancer: a phase 1a/1b trial.Nat Commun15, 5158 (2024). https://doi.org/10.1038/s41467-024-48798-w


















Contacts


Iksuda Therapeutics
Dave Simpson, Chief Executive Officer
Tel: +44 (0) 191 6031680
Emailinfo@iksuda.com

FTI Consulting (Financial Media and IR)
Simon Conway / Rob Winder / Amy Byrne
Tel: +44 (0) 020 3727 1000
Iksuda@fticonsulting.com





=*=*=*=*=*=
当前为第6/6页
上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页